Publicacions en què col·labora amb MARTA ALVAREZ ESTEVEZ (30)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2022

  1. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  2. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2020

  1. Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: A multicentre cohort study

    AIDS Research and Therapy, Vol. 17, Núm. 1

  2. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study

    The Lancet HIV, Vol. 7, Núm. 8, pp. e565-e573

  3. Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient

    Antiviral Research, Vol. 179

  4. How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain

    HIV Medicine, Vol. 21, Núm. 2, pp. 128-134

2019

  1. Spatiotemporal characteristics of the largest HIV-1 CRF02_AG outbreak in Spain: Evidence for onward transmissions

    Frontiers in Microbiology, Vol. 10, Núm. MAR

  2. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

    The Journal of antimicrobial chemotherapy, Vol. 74, Núm. 6, pp. 1693-1700

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach

    PLoS ONE, Vol. 12, Núm. 10

  2. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

  3. The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice

    PLoS ONE, Vol. 12, Núm. 4

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  2. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

  3. Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain

    PLoS ONE, Vol. 11, Núm. 12

  4. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe

    Clinical Infectious Diseases, Vol. 62, Núm. 5, pp. 655-663

  5. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure

    BMC Infectious Diseases, Vol. 16, Núm. 1